Bisphosphonate treatment in the oim mouse model alters bone modeling during growth
| Autor: | S. H. Rao, K.D. Evans, Anita M. Oberbauer, R. B. Martin |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Osteoporosis Long bone Biomedical Engineering Biophysics Pamidronate Dentistry Article Bone remodeling Mice Internal medicine Animals Medicine Orthopedics and Sports Medicine Femur Bone Development Diphosphonates Dose-Response Relationship Drug business.industry Rehabilitation Organ Size Osteogenesis Imperfecta Bisphosphonate medicine.disease Disease Models Animal Treatment Outcome Endocrinology medicine.anatomical_structure Osteogenesis imperfecta Female Bone Remodeling business Type I collagen |
| Zdroj: | Journal of Biomechanics. 41:3371-3376 |
| ISSN: | 0021-9290 |
| Popis: | Osteogenesis imperfecta (OI) is a heritable disease, which results from an abnormal amount or structure of Type I collagen. Bisphosphonates, a class of synthetic antiresorptive drugs, used in osteoporosis management, are also used to decrease fracture incidence and improve quality of life in children with OI. In this study, we used the oim mouse to test the hypotheses that pamidronate treatment during active growth (1) produces larger, stronger, stiffer long bone diaphyses without altering bone material properties, and (2) negatively impacts longitudinal bone growth. Our results indicate that femoral cross-sectional moment of inertia in the distal metaphysis tended to increase with pamidronate treatment and that the treated bones are thicker and structurally stiffer, but shorter than their control-dose counterparts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect